AstraZeneca Plc reported better-than-expected profit and revenue in the fourth quarter and forecast further gains, helped by ...

Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...

AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter 2024. The London-listed company ...

Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with ...

Astrazeneca's revenue jumped 21 per cent last year as the pharmaceutical recorded broad growth across its key businesses.

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy ...

AstraZeneca's Imfinzi has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

AstraZeneca PLC on Thursday ended a strong year with better-than-expected fourth quarter earnings and said its pipeline would support further growth in 2025. The Cambridge-based pharmaceuticals firm ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

(Alliance News) - AstraZeneca PLC on Monday said Imfinzi has been recommended for approval in the EU as monotherapy for limited-stage small cell lung cancer.